GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Accounts Receivable

Mesoblast (ASX:MSB) Accounts Receivable : A$2.31 Mil (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Mesoblast's accounts receivables for the quarter that ended in Dec. 2024 was A$2.31 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Mesoblast's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was A$-0.19.


Mesoblast Accounts Receivable Historical Data

The historical data trend for Mesoblast's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Accounts Receivable Chart

Mesoblast Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.98 2.62 3.17 3.39 2.11

Mesoblast Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 - 2.11 - 2.31

Mesoblast Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Mesoblast Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Mesoblast's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=2.31/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Mesoblast's accounts receivable are only considered to be worth 75% of book value:

Mesoblast's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(59.459+0.75 * 2.31+0.5 * 38.202-303.256
-0-0)/1156.509
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Mesoblast Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Mesoblast's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast Business Description

Traded in Other Exchanges
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Mesoblast Headlines

From GuruFocus

Mesabi Trust Stock Appears To Be Significantly Overvalued

By GF Value GF Value 04-30-2021

MSB Stock Drops 5.12% Amid Low Trading Volume

By GuruFocus Research 09-27-2024

Top 5 4th Quarter Trades of MAD RIVER INVESTORS

By GuruFocus Research GuruFocus Editor 02-06-2023

Mesabi Trust Press Release

By Business Wire 05-02-2024

Mesabi Trust Stock Appears To Be Significantly Overvalued

By GF Value GF Value 06-10-2021

Mesabi Trust Press Release

By Business Wire 01-12-2024

Mesabi Trust Press Release

By Business Wire 10-13-2023

MESABI TRUST Announces Arbitration Final Award

By Business Wire 09-10-2024

Mesabi Trust Press Release

By Business Wire Business Wire 10-14-2022